Eisai's announcement that lecanemab, its antibody drug for Alzheimer’sdisease that targets the buildup of amyloid protein in the brain, modestly slowed cognitive decline in a Phase 3 trial offers hope to people with Alzheimer’s disease. But what I’ll be looking for in the final data — which have not yet been presented or published — is whether the brain shrinkage seen in the Phase 2 trial remains.

Read PDF: Brain shrinkage needs closer scrutiny in trials of anti-amyloid drugs